Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2020

Aug 07, 2020

SELL
$6.4 - $9.5 $2,201 - $3,268
-344 Closed
0 $0
Q1 2020

May 04, 2020

BUY
$5.06 - $22.0 $713 - $3,102
141 Added 69.46%
344 $2,000
Q4 2019

Feb 04, 2020

BUY
$16.6 - $27.0 $3,369 - $5,481
203 New
203 $3,000

Others Institutions Holding MNPR

About Monopar Therapeutics


  • Ticker MNPR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 12,725,800
  • Market Cap $86.2M
  • Description
  • Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe ...
More about MNPR
Track This Portfolio

Track Victory Capital Management Inc Portfolio

Follow Victory Capital Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Victory Capital Management Inc with notifications on news.